Therapeutic use of VEGF-C and CCBE1

Alitalo, Kari

WIPO
2015-02-19


http://hdl.handle.net/10138/175295

Downloaded from Helda, University of Helsinki institutional repository.
This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.
Please cite the original version.
International Application Status Report

Received at International Bureau: 21 August 2014 (21.08.2014)
Information valid as of: 21 September 2015 (21.09.2015)
Report generated on: 01 July 2016 (01.07.2016)

(10) Publication number: WO2015/022447
(43) Publication date: 19 February 2015 (19.02.2015)
(26) Publication language: English (EN)

(21) Application Number: PCT/FI2014/050620
(22) Filing Date: 13 August 2014 (13.08.2014)
(25) Filing language: English (EN)

(31) Priority number(s): 20135832 (FI)
(31) Priority date(s): 14 August 2013 (14.08.2013)
(31) Priority status: Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61P 7/00 (2006.01); A61P 7/10 (2006.01)

(71) Applicant(s):
LAURANTIS PHARMA OY [FI/FI]; Itäinen Pitkäkatu 4 B FI-20520 Turku (FI) (for all designated states)

(72) Inventor(s):
ALITALO, Kari; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)
JELTSCH, Michael; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)
ANISIMOV, Andrey; c/o Molecular/Cancer Biology Laboratory Biomedicum FI-00014 Helsinki (FI)

(74) Agent(s):
KOLSTER OY AB; Iso Roobertinkatu 23 P.O.Box 148 FI-00121 Helsinki (FI)

(54) Title (EN): THERAPEUTIC USE OF VEGF-C AND CCBE1
(54) Title (FR): UTILISATION THÉRAPEUTIQUE DE VEGF-C ET DE CCBE1

(57) Abstract:
(EN): The present invention relates to therapeutic methods, us- es and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lym- phatic system, particularly lymphedema.

(FR): La présente invention concerne des procédés thérapeutiques, des utilisations et des compositions comprenant CCBE1 et VEGF-C pour traiter des troubles et des états impliquant une déficience du système lymphatique, notamment un lymphédème.

International search report:
Received at International Bureau: 17 November 2014 (17.11.2014) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Chapter II demand received: 11 June 2015 (11.06.2015)

(81) Designated States:
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

**Declarations:**
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate
Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America